Article citationsMore>>

Finn, V., Kolodgie, F.D., Harnek, J., Guerrero, L., Acampado, E., Tefera, K., Skorija, K., Weber, D.K., Gold, H.K. and Virmani, R. (2005) Differential Response of Delayed Healing and Persistent Inflammation at Sites of Overlapping Sirolimusor Paclitaxel-Eluting Stents. Circulation, 112, 270-278.
http://dx.doi.org/10.1161/CIRCULATIONAHA.104.508937

has been cited by the following article:

• TITLE: Clinical Performance of the Cobalt-Chromium Biodegradable Polymer Coated Sirolimus-Eluting Stent in an Unselected Real-World Population

  AUTHORS: Prakash Chandwani, Atul D. Abhyankar, Jayesh S. Prajapati, Sanjay C. Porwal, Ashok S. Thakkar

  KEYWORDS: Coronary Artery Disease; Biodegradable Polymer; Sirolimus-Eluting Stent

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.5 No.5, March 18, 2014

  ABSTRACT: OBJECTIVE: The primary objective of the S-CORE registry was to assess the safety and efficacy of the Supralimus-Core? sirolimus-eluting stent deployment for the treatment of coronary artery disease and event-free survival of patients treated with this coronary stent. METHODS: S-CORE Registry is an observational, single-arm, non-randomized, post-marketing surveillance multicenter registry in which 562 patients undergoing single or multi-vessel percutaneous coronary intervention were enrolled. The pre-specified primary outcome was the rate of major adverse cardiac events (MACE), defined as the composite of cardiac death, myocardial infarction (MI), target lesion revascularisation (TLR) and target vessel revascularisation (TVR) at 12-month post-procedure. Stent thrombosis (ST) served as the safety endpoint. RESULTS: A total of 640 lesions were treated in 562 enrolled patients (mean age 57.4 ± 10.7 years) with average stent length of 25.0 ± 9.0 mm. Stent delivery was successful in 99% cases. A total of 554 (98.6%) patients have been followed up to 12 months. The incidence of MACE at 30 days and 6 months was 7 (1.2%) and 12 (2.1%) respectively. The composite rate of MACE at a 12-month clinical follow-up was 19 (3.4%), consisting of 12 (2.1%) cardiac deaths, 0 (0%) MI, 6 (1.1%) TLR and 1 (0.2%) TVR. The long-term follow-up of this registry is going on to confirm safety and efficacy profiles. CONCLUSIONS: This multicenter registry demonstrated satisfactory safety and efficacy profiles, as evidenced by low rates of major adverse cardiac events up to 12 months, for the cobalt-chromium biodegradable polymer-based sirolimus-eluting Supralimus-Core? stent in a “real-world” setting.